Cosmo First Ltd

Q2 FY24 Earnings Call Analysis

Industrial Products

Full Stock Analysis
fundraise: Nocapex: Yesrevenue: Category 3margin: Category 3orderbook: No information
πŸ’°

fundraise

Any current/future new fundraising through debt or equity?

- The company currently operates with a total debt of close to Rs. 600 crores, with a debt-to-EBITDA ratio of around 2.1. - Management does not expect any significant change or increase in debt levels in the current year. - For the next year, with lower Capex planned, the company expects the debt to come down. - There are no indications or announcements regarding any new fundraising through equity or additional debt in the near term. - Management specifically mentioned "Nothing on the cards for this year" regarding any demerger or structural changes. - Overall, the company plans to maintain or reduce debt levels post FY25 despite ongoing and planned Capex.
πŸ—οΈ

capex

Any current/future capex/capital investment/strategic investment?

- Capex of roughly Rs. 300 crores planned for FY25 and around Rs. 150 crores for FY26, including maintenance. - Major investments include commissioning a new CPP line expected in Q3 FY25 and parts in Q4 FY25. - A new BOPP line is expected to start commercial production by H1 FY26; both CPP and BOPP lines will be among the world’s largest, increasing production capacity by ~50%. - Small Capex planned for specialty chemicals expansion by end of FY25 or FY26, but not sizable. - Thermal film line relocated from Korea to India; commercial production expected from Q3 FY25. - No plans for any demerger in the current year. - Net debt (~Rs. 600 crore) expected to remain stable this year and reduce next year despite Capex.
πŸ“Š

revenue

Future growth expectations in sales/revenue/volumes?

- The company expects improved sales of specialty films during FY25, with specialty volumes increasing progressively (69% in Q1 FY25). - Domestic BOPP margins are expected to remain healthy throughout FY25. - New business verticals like specialty chemicals are already generating decent EBITDA, with rigid packaging expected to earn EBITDA by FY25-end. - Zigly (pet care vertical) is in growth phase; profitability is anticipated but may take a couple of years. - Sun control films commercial production will begin Q4 FY25, with meaningful profitability expected from FY27. - Polyester (BOPET) margins showed improvement; profitability expected to grow as demand improves in coming quarters. - Company targets roughly 5-10% volume growth next year from CPP new line and other capacity expansions. - Export demand remains strong, contributing to growth alongside new domestic startups in FMCG-related flexible packaging segments.
πŸ“ˆ

margin

Future growth expectations in earnings/operating earnings/profits/EPS?

- Company expects improved sales of specialty films and healthier domestic BOPP margins during FY25. - Specialty sales increased to 69% of total volume in Q1 FY25, up from 64% in FY24, indicating higher-margin product mix. - Specialty chemicals vertical already generating decent EBITDA in mid-teens; rigid packaging expected to be EBITDA-positive by FY25-end. - BOPET business made positive EBITDA in Q1; margins expected to improve as demand rises and utilization increases. - Sun control window films commercial production starts Q4 FY25; meaningful profitability anticipated only from FY27. - Zigly (pet care) business remains in growth phase; profitability forecasted after a couple of years. - Renewable power initiatives expected to contribute ~Rs. 25 crores annual bottom-line benefit from FY25. - Capex of approx. Rs. 300 crore in FY25, Rs. 150 crore in FY26, aimed at capacity expansion and specialty products. - Net debt expected to stabilize in FY25 and reduce in FY26, supporting financial health and earnings growth.
πŸ“‹

orderbook

Current/ Expected Orderbook/ Pending Orders?

The transcript does not explicitly mention any details regarding the current or expected order book or pending orders for Cosmo First Limited. The discussion focuses primarily on: - Capacity utilization and commercialization timelines (e.g., sun control films expected commercial production from Q4 FY25). - EBITDA and profitability outlooks for various verticals like specialty chemicals, BOPP, BOPET, and Zigly. - Capex plans and debt position. - Margin and spread improvements in BOPP and BOPET segments. - Growth outlook for specialty films and flexible packaging demand trends. No direct information on order book size or pending orders is disclosed in the provided transcript.